Chemotherapy Devices Market to Hit US$ 21.58 billion by 2032, Says Growth Plus Reports
Growth Plus Reports
Updated 6 min read
Growth Plus Reports
Newark, New Castle, USA, June 20, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the chemotherapy devices market was valued at US$ 11.84 billion and is expected to rise at a revenue CAGR of 6.9% to reach US$ 21.58 billion by 2031.
The global market for chemotherapy devices was analyzed, and it is expected to increase significantly during the forecast period. Chemotherapy devices are medical devices that employ chemotherapy medications to treat cancer. Chemotherapy is a form of systemic medicine that uses drugs to kill or halt the development of cancer cells.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Recent Development in the Global Chemotherapy Devices Market:
In March 2023, a collaboration between Eversana and ChemoMouthpiece will promote the medical device's introduction and commercialization in the United States. The Chemo Mouthpiece device, an intraoral ice pack, helps cancer patients manage and cure oral mucositis, an unpleasant side effect of chemotherapy.
In March 2023, The FDA authorized a single-dose, prefilled autoinjector version of Coherus Biosciences' pegfilgrastim biosimilar for the prevention and treatment of febrile neutropenia, a common chemo side effect.
Key Takeaways:
Increasing cancer prevalence and its awareness are driving the market revenue share.
With the advancement of technology, there is a significantly increasing demand for chemotherapy treatments.
Several government initiatives and increased availability of reimbursement policies are boosting market revenue growth.
The market revenue is expected to grow substantially as cancer incidences rise, government health regulations improve, and reimbursement availability expands. Moreover, the introduction of innovative and advanced chemotherapeutic devices with greater efficacy and fewer side effects is also fueling the growth of the global chemotherapy devices market revenue.
However, a rigorous regulatory framework, requirement for complex production techniques and skill sets, utilization of transgenic animals and plants, and ethical concerns regarding animal sources all limit the market revenue growth.
Market Segmentation:
Segmentation By Product Type
Based on product types, the global chemotherapy devices market is segmented into catheters, cannulas, infusion pumps, and others. Due to the accurate and precise delivery of medications, the infusion pump segment accounts for the largest market revenue share, lowering the possibility of human mistakes and ensuring patients receive the right dosage.
Segmentation By End-User
Based on the end-user, the global chemotherapy devices market is segmented into hospitals, homecare settings, and clinics. The variables that contribute to a growth in the frequency of hospital visits and hospital stays globally boost demand for the hospital segment, resulting in the dominance of this segment over others.
Regional Growth Dynamics
Based on the region, the global chemotherapy devices market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Due to the increased cancer prevalence, rising demand for chemotherapy equipment, technical breakthroughs in chemotherapy devices, and an aging population, North America accounts for the most significant revenue share in the global market.
Competitive Landscape
The following is a list of the prominent players in the global market for chemotherapy devices:
ICU Medical
Fresenius Kabi
Advanced Chemotherapy Technologies
B. Braun Melsungen AG
Baxter International Inc.
Report Coverage
Growth Plus reports studied the global market for chemotherapy devices in-depth and analyzed the basic market characteristics, significant investment opportunities, analytics of regional growth, revenue forecasting, competitive market players, mergers, and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL BENCHTOP AUTOMATION MARKET - ANALYSIS & FORECAST, BY PRODUCT TYPE
Catheters
Cannulas
Syringe Pumps
Others
GLOBAL BENCHTOP AUTOMATION MARKET - ANALYSIS & FORECAST, BY END USER
Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031
Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
